Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

Authors: Rebecca A. Dent, Sung-Bae Kim, Mafalda Oliveira, Carlos Barrios, Joyce O’Shaughnessy, Steven J. Isakoff, Shigehira Saji, Ruffo Freitas-Junior, Manuel Philco, Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew J. Wongchenko, Sarah-Jayne Reilly, Nicholas Turner

Contributors: Institut Català de la Salut, [Dent RA] Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. Duke-NUS Medical School, Singapore, Singapore. [Kim SB] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. [Oliveira M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Barrios C] Latin American Cooperative Oncology Group (LACOG), Oncoclínicas, Porto Alegre, Brazil. [O’Shaughnessy J] Department of Medical Oncology, Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, Texas. [Isakoff SJ] Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, Vall d'Hebron Barcelona Hospital Campus, Turner, Nicholas

Source: Clin Cancer Res
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor, Paclitaxel, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Class I Phosphatidylinositol 3-Kinases, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales, Clinical Trials: Targeted Therapy, Triple Negative Breast Neoplasms, Quimioteràpia combinada, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Piperazines, Double-Blind Method, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Biomarkers, Tumor, Humans, Aged, Aged, 80 and over, Tumor, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Marcadors tumorals, PTEN Phosphohydrolase, Middle Aged, Progression-Free Survival, Pyrimidines, Mama - Càncer - Tractament, Female, Proto-Oncogene Proteins c-akt, Biomarkers

File Description: application/pdf; Print

Access URL: https://pubmed.ncbi.nlm.nih.gov/39058425
https://hdl.handle.net/11351/12225

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

Authors: Rebecca Kristeleit, Alexandra Leary, Ana Oaknin, Andres Redondo, Angela George, Stephen Chui, Aicha Seiller, Mario Liste-Hermoso, Jenna Willis, Colby S. Shemesh, Jim Xiao, Kevin K. Lin, Luciana Molinero, Yinghui Guan, Isabelle Ray-Coquard, Linda Mileshkin

Contributors: Institut Català de la Salut, [Kristeleit R] University College London Cancer Institute, London, UK. School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK. Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, UK. [Leary A] Gustave Roussy, Villejuif, France. [Oaknin A] Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Redondo A] Medical Oncology Department, La Paz University Hospital-IdiPAZ, Madrid, Spain. [George A] The Institute of Cancer Research, London, UK. Royal Marsden NHS Foundation Trust, London, UK. [Chui S] Product Development Oncology, Genentech Inc., South San Francisco, CA, USA, Vall d'Hebron Barcelona Hospital Campus

Source: Br J Cancer
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Adult, 0301 basic medicine, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Indoles, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Triple Negative Breast Neoplasms, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Poly(ADP-ribose) Polymerase Inhibitors, Antibodies, Monoclonal, Humanized, Quimioteràpia combinada, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Article, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Ovarian Neoplasms, Anticossos monoclonals - Ús terapèutic, BRCA1 Protein, Ovaris - Càncer - Tractament, Middle Aged, Mama - Càncer - Tractament, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas, Female, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38971950
https://hdl.handle.net/11351/11954

The impact of a high fat diet and platelet activation on pre-metastatic niche formation

Authors: Marta Hergueta-Redondo, Sara Sánchez-Redondo, Begoña Hurtado, Vanesa Santos, Manuel Pérez-Martínez, Pilar Ximénez- Embún, Sheri A. C. McDowell, Marina S. Mazariegos, Gadea Mata, Raúl Torres-Ruiz, Sandra Rodríguez-Perales, Lola Martínez, Osvaldo Graña-Castro, Diego Megias, Daniela Quail, Miguel Quintela-Fandino, Héctor Peinado

Contributors: Institut Català de la Salut, [Hergueta-Redondo M, Sánchez-Redondo S, Santos V] Microenvironment and Metastasis Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Center (CNIO), Madrid, Spain. [Hurtado B] Cancer Cell Cycle Group, Preclinical & Translational Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pérez-Martínez M] Confocal Microscopy Unit, Biotechnology Programme, Spanish National Cancer Research Center (CNIO), Madrid, Spain. [Ximénez-Embún P] Proteomics Unit, Biotechnology Programme, Spanish National Cancer Research Center (CNIO), Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Nat Commun
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Nature Communications, Vol 16, Iss 1, Pp 1-21 (2025)

Subject Terms: Blood Platelets, Lung Neoplasms, Science, FENÓMENOS Y PROCESOS::fenómenos fisiológicos respiratorios y circulatorios::fenómenos fisiológicos sanguíneos::hemostasia::activación plaquetaria, Triple Negative Breast Neoplasms, Hemostàsia, Greix, FENÓMENOS Y PROCESOS::fenómenos fisiológicos::dieta, alimentación y nutrición::fenómenos fisiológicos nutricionales::dieta::alimentación rica en grasa, Diet, High-Fat, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Article, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, PHENOMENA AND PROCESSES::Physiological Phenomena::Diet, Food, and Nutrition::Nutritional Physiological Phenomena::Diet::Diet, High-Fat, Mice, Mama - Càncer, Metàstasi, Cell Line, Tumor, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Tumor Microenvironment, Humans, Animals, PHENOMENA AND PROCESSES::Circulatory and Respiratory Physiological Phenomena::Blood Physiological Phenomena::Hemostasis::Platelet Activation, Neoplasm Metastasis, FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral, ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica, Endothelial Cells, Platelet Activation, Fibronectins, DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis, Other subheadings::Other subheadings::Other subheadings::/adverse effects, PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment, Female, Malalties d'origen nutricional

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/40175356
http://hdl.handle.net/11351/13048
https://doaj.org/article/b36a720546284137a6264c47ea1beeb1

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

Authors: Peter Schmid, Mafalda Oliveira, Joyce O’Shaughnessy, Massimo Cristofanilli, Stephanie L. Graff, Seock-Ah Im, Sherene Loi, Shigehira Saji, Shusen Wang, David W. Cescon, Tina Hovey, Agata Nawrot, Karson Tse, Petra Vukovic, Giuseppe Curigliano

Contributors: Institut Català de la Salut, [Schmid P] Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. [Oliveira M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [O’Shaughnessy J] Texas Oncology, Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA. [Cristofanilli M] Department of Medicine, Weill Cornell Medicine, New York, NY, USA. [Graff Brown SL] University Health Cancer Institute, Legorreta Cancer Center, Brown University, Providence, RI, USA. [ImSA] Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea, Vall d'Hebron Barcelona Hospital Campus

Source: Ther Adv Med Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Therapeutic Advances in Medical Oncology, Vol 17 (2025)

Subject Terms: CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Anticossos monoclonals - Ús terapèutic, Other subheadings::Other subheadings::/therapeutic use, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Otros calificadores::Otros calificadores::/uso terapéutico, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Antibody-drug conjugates in breast oncology: new standards, emerging challenges, and future directions, Quimioteràpia combinada, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Mama - Càncer - Tractament, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, RC254-282

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/40297626
http://hdl.handle.net/11351/13216
https://doaj.org/article/899769d47504498aa346954428f1d306

3D Bioprinted Tumor-Stroma Models of Triple-Negative Breast Cancer Stem Cells for Preclinical Targeted Therapy Evaluation

Authors: Patricia González-Callejo, Clara García-Astrain, Ada Herrero-Ruiz, Malou Henriksen-Lacey, Joaquín Seras-Franzoso, Ibane Abasolo, Luis M. Liz-Marzán

Contributors: Institut Català de la Salut, [González-Callejo P] CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Spain. [García-Astrain C, Herrero-Ruiz A, Henriksen-Lacey M] CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Spain. Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain. [Seras-Franzoso J] Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain. Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Abasolo I] Centro de Investigación Biomédica en Red, Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain. Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Bioquímica Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: ACS Appl Mater Interfaces
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
ACS Applied Materials & Interfaces

Subject Terms: Medicaments antineoplàstics - Ús terapèutic, Triple Negative Breast Neoplasms, Antineoplastic Agents, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Triple-negative breast cancer, Cell Line, Tumor, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Tumor Microenvironment, Humans, FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral, 3D bioprinting, Cancer stem cells, SERS, TECHNOLOGY, INDUSTRY, AND AGRICULTURE::Technology, Industry, and Agriculture::Technology::Printing, Three-Dimensional, Bioprinting, Tumor microenvironment, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos, ANATOMÍA::células::células madre::células madre neoplásicas, Mama - Càncer - Tractament, PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment, Printing, Three-Dimensional, Neoplastic Stem Cells, TECNOLOGÍA, INDUSTRIA Y AGRICULTURA::tecnología, industria y agricultura::tecnología::impresión tridimensional, Female, Stromal Cells, Cèl·lules mare, Impressió 3D, ANATOMY::Cells::Stem Cells::Neoplastic Stem Cells, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38764168
https://hdl.handle.net/11351/11556
https://ddd.uab.cat/record/311345

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

Authors: Aditya Bardia, Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Kevin Kalinsky, Javier Cortés, Joyce O' Shaughnessy, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine Piccart-Gebhart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara A. Hurvitz

Contributors: Institut Català de la Salut, [Bardia A] Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA. [Rugo HS] University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. [Tolaney SM] Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. [Loirat D] Institut Curie, Paris, France. [Punie K] Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. [Oliveira M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: J Clin Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Journal of Clinical Oncology, vol 42, iss 15

Subject Terms: Adult, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Immunoconjugates, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Receptor, ErbB-2, Triple Negative Breast Neoplasms, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados, Antibodies, Monoclonal, Humanized, Antibodies, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, ErbB-2, Antigens, Neoplasm, Monoclonal, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Humans, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates, Antigens, Neoplasm Metastasis, Humanized, Aged, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Middle Aged, Progression-Free Survival, 3. Good health, CLINICAL TRIAL UPDATES, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Mama - Càncer - Tractament, Avaluació de resultats (Assistència sanitària), Neoplasm, Female, Camptothecin, Cell Adhesion Molecules, Receptor

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38422473
https://hdl.handle.net/11351/11480
https://escholarship.org/uc/item/3271x9mg
https://escholarship.org/content/qt3271x9mg/qt3271x9mg.pdf

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

Authors: Rebecca Dent, Javier Cortés, Yeon Hee Park, Eva Muñoz-Couselo, Sung-Bae Kim, Joohyuk Sohn, Seock-Ah Im, Esther Holgado, Theodoros Foukakis, Sherko Kümmel, Jennifer Yearley, Anran Wang, Michael Nebozhyn, Lingkang Huang, Razvan Cristescu, Petar Jelinic, Vassiliki Karantza, Peter Schmid

Contributors: Institut Català de la Salut, [Dent R] Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. [Cortés J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. International Breast Cancer Center, Quironsalud Group, Barcelona, Spain. Department of Medicine, Faculty of Biomedical and Health Sciences, European University of Madrid, Madrid, Spain. [Park YH] Department of Medicine, Division of Hematology Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. [Muñoz Couselo E] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Kim SB] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. [Sohn J] Department of Internal Medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Vall d'Hebron Barcelona Hospital Campus

Source: Breast Cancer Res
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Breast Cancer Research, Vol 27, Iss 1, Pp 1-12 (2025)

Subject Terms: Adult, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Other subheadings::Other subheadings::/therapeutic use, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Otros calificadores::Otros calificadores::/uso terapéutico, Triple Negative Breast Neoplasms, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Antibodies, Monoclonal, Humanized, Quimioteràpia combinada, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy, Lymphocytes, Tumor-Infiltrating, Triple-negative breast cancer, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::tratamiento neoadyuvante, Antineoplastic Combined Chemotherapy Protocols, Tumor Microenvironment, Biomarkers, Tumor, Humans, FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral, RC254-282, Neoplasm Staging, Aged, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Immunohistochemistry, Neoadjuvant Therapy, Treatment Outcome, Tumor microenvironment, Mama - Càncer - Tractament, PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment, Mama - Càncer - Aspectes genètics, Female

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/40069763
http://hdl.handle.net/11351/12956
https://doaj.org/article/4b4962b9db324675a0d0e9eac3dbd9f3

Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

Authors: Lopez-Tarruella, Sara, Pollán, Marina, Carrasco, Eva, ANDRES, RAQUEL, Martin, Miguel, Marín, María, Servitja Tormo, Sonia

Contributors: Lopez-Tarruella S, Martín Miguel Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, Spain. Fundación Grupo Español de Investigación en Cáncer de Mama (GEICAM), Madrid, Spain. Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III (ISCIII), Spain. Pollán M Fundación Grupo Español de Investigación en Cáncer de Mama (GEICAM), Madrid, Spain. Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III (ISCIII), Spain. Centro Nacional de Epidemiología. Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Carrasco E Fundación Grupo Español de Investigación en Cáncer de Mama (GEICAM), Madrid, Spain. Andrés R Fundación Grupo Español de Investigación en Cáncer de Mama (GEICAM), Madrid, Spain. Hospital del Mar, Barcelona, Spain. Servitja S Fundación Grupo Español de Investigación en Cáncer de Mama (GEICAM), Madrid, Spain. Hospital del Mar, Barcelona, Spain. Marín M Fundación Grupo Español de Investigación en Cáncer de Mama (GEICAM), Madrid, Spain. Consorci Sanitari de Terrassa, Terrassa, Spain, Consorci Sanitari de Terrassa

Source: Scientia

Subject Terms: Mama - Càncer - Tractament, Pacients - Satisfacció, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, HEALTH CARE::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Survival Analysis::Disease-Free Survival, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, ATENCIÓN DE SALUD::calidad, acceso y evaluación de la atención sanitaria::calidad de la atención sanitaria::mecanismos de evaluación de la atención sanitaria::estadística como asunto::análisis de supervivencia::supervivencia sin enfermedad

File Description: application/pdf

Relation: The Oncologist;30(4); https://www.doi.org/10.1093/oncolo/oyaf040; https://hdl.handle.net/11351/13607

Availability: https://hdl.handle.net/11351/13607
https://doi.org/10.1093/oncolo/oyaf040

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Authors: Ring, Alistair, Kilburn, Lucy S, Pearson, Alex, Moretti, Laura, Afshari-Mehr, Angelica, Wardley, Andrew M, Gurel, Bora, Macpherson, Iain R, Riisnaes, Ruth, Baird, Richard D, Martin, Sue, Roylance, Rebecca, Johnson, Hannah, Ferreira, Ana, Winter, Matthew C, Dunne, Kathryn, Copson, Ellen, Hickish, Tamas, Burcombe, Russell, Randle, Kat, Serra, Violeta, Llop-Guevara, Alba, Bliss, Judith M, Turner, Nicolas C

Contributors: Institut Català de la Salut, [Ring A] Breast Unit, The Royal Marsden Hospital, Sutton, United Kingdom. Division of Breast Cancer Research, Institute of Cancer Research, London, United Kingdom. [Kilburn LS, Moretti L] Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom. [Pearson A, Afshari-Mehr A] The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom. [Wardley AM] Outreach Research & Innovation Group, Manchester, United Kingdom. [Serra V, Llop-Guevara A] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, DSpace at Cambridge pro (8.1), Kilburn, Lucy, Pearson, Alex, Gurel, Bora, Bliss, Judith, Turner, Nicholas

Source: Clin Cancer Res
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: BRCA2 Protein, BRCA1 Protein, Medicaments antineoplàstics - Ús terapèutic, Clinical Trials: Targeted Therapy, Triple Negative Breast Neoplasms, Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, 3. Good health, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos, Mama - Càncer - Tractament, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Humans, Phthalazines, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents

File Description: application/pdf; Print-Electronic

Access URL: https://pubmed.ncbi.nlm.nih.gov/37773077
https://hdl.handle.net/11351/10724
https://www.repository.cam.ac.uk/handle/1810/357918
https://doi.org/10.1158/1078-0432.ccr-23-1696
https://doi.org/10.17863/cam.101870

Tractament del càncer de mama metastàtic HER2 positiu

Authors: Programa d'Harmonització Farmacoterapèutica

Contributors: Departament de Salut

Source: Scientia

Subject Terms: Mama - Càncer - Tractament, Metàstasi, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Catalonia, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Cataluña

File Description: application/pdf

Relation: Informe d'utilització i seguiment de resultats; Programa d'Harmonització Farmacoterapèutica. Tractament del càncer de mama metastàtic HER2 positiu. Barcelona: Servei Català de la Salut; 2025. (Informe d'utilització i de seguiment de resultats).; https://hdl.handle.net/11351/13854

Availability: https://hdl.handle.net/11351/13854
https://doi.org/10.62727/DSalut.SCS/13854

Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report

Authors: Jesús Yaringaño, María Roca-Herrera, Simeón Eremiev, Pau Mascaró-Baselga, Pau Benito, Fidel Núñez, Sergi Benavente, Isabel Pimentel

Contributors: Institut Català de la Salut, [Yaringaño J, Roca-Herrera M, Eremiev S, Mascaró-Baselga P, Benito P] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Núñez F] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Benavente S] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Radioteràpica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pimentel I] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Front Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Frontiers in Oncology, Vol 14 (2024)

Subject Terms: 0301 basic medicine, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, leptomeningeal carcinomatosis, Otros calificadores::Otros calificadores::/uso terapéutico, Sistema nerviós central - Càncer - Tractament, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, antibody-drug conjugate, sacituzumab govitecan, 03 medical and health sciences, 0302 clinical medicine, Metàstasi, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates, RC254-282, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, DISEASES::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms::Meningeal Neoplasms::Meningeal Carcinomatosis, Oncology, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema nervioso::neoplasias del sistema nervioso central::neoplasias meníngeas::carcinomatosis meníngea, Mama - Càncer - Tractament, triple-negative breast cancer, partial response

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39188688
https://hdl.handle.net/11351/12644
https://doaj.org/article/a76af0ab0d714185970966c3be5c38a3

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

Authors: Loibl, Sibylle, Loirat, Delphine, Tolaney, Sara M., Punie, Kevin, Oliveira, Mafalda, Rugo, Hope S., Bardia, Aditya, Hurvitz, Sara A., Brufsky, Adam M., Kalinsky, Kevin, Cortes, Javier, O'Shaughnessy, Joyce A., Dieras, Veronique, Carey, Lisa A., Gianni, Luca, Gharaibeh, Mahdi, Preger, Luciana, Phan, See, Chang, Lawrence, Shi, Ling, Piccart, Martine J.

Contributors: Institut Català de la Salut, [Loibl S] Hämatologisch-Onkologische Gemeinschaftspraxis Am Bethanien-Krankenhaus, Frankfurt, Germany. [Loirat D] Medical Oncology Department and D3i, Institut Curie, Paris, France. [Tolaney SM] Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. [Punie K] Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. [Oliveira M] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Rugo HS] Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA, Vall d'Hebron Barcelona Hospital Campus

Source: Eur J Cancer
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Quality of life, Adult, Immunoconjugates, LONG-TERM, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Pain, Triple Negative Breast Neoplasms, HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados, Sacituzumab govitecan, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Article, 1117 Public Health and Health Services, 03 medical and health sciences, Phase III, 0302 clinical medicine, 3211 Oncology and carcinogenesis, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Humans, 1112 Oncology and Carcinogenesis, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates, Oncology & Carcinogenesis, Antibody-drug conjugate, ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida, Fatigue, Triple-negative breast neoplasms, Science & Technology, Other subheadings::Other subheadings::Other subheadings::/drug therapy, EORTC QLQ-C30, Immunoglobulines - Ús terapèutic, 3. Good health, Cancérologie, Clinical trial, Oncology, Mama - Càncer - Tractament, Quality of Life, Antibody–drug conjugate, Life Sciences & Biomedicine, Qualitat de vida - Avaluació

File Description: application/pdf; 1 full-text file(s): application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/36379186
https://hdl.handle.net/11351/9004

Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

Authors: Cortes, Javier, Winer, Eric P, Lipatov, Oleg, Im, Seock‐Ah, Gonçalves, Anthony, Muñoz‐Couselo, Eva, Lee, Keun Seok, Schmid, Peter, Tamura, Kenji, Testa, Laura, Witzel, Isabell, Ohtani, Shoichiro, Hund, Stephanie, Kulangara, Karina, Karantza, Vassiliki, Mejia, Jaime A, Ma, Junshui, Jelinic, Petar, Huang, Lingkang, Pruitt, Scott K, Emancipator, Kenneth

Contributors: Institut Català de la Salut, [Cortes J] Oncology Department, International Breast Cancer Center (BCC), Pangaea Oncology, Quirónsalud, Barcelona, Spain. Department of Medicine, Faculty of Biomedical and Health Sciences, European University of Madrid, Madrid, Spain. [Winer EP] Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA. [Lipatov O] Department of Oncology, Republican Clinical Oncology Dispensary of the Ministry of Public Health of Bashkortostan Republic, Ufa, Russia. [Im SA] Department of Internal Medicine, Seoul National University Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea. [Gonçalves A] Aix Marseille University, CNRS, INSERM, Department of Medical Oncology, Institut Paoli-Calmettes, CRCM, Marseille, France. [Muñoz-Couselo E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, collette, yves, University of Zurich, Cortes, Javier

Source: J Pathol Clin Res
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
The Journal of Pathology: Clinical Research, Vol 10, Iss 3, Pp n/a-n/a (2024)

Subject Terms: CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales, 610 Medicine & health, Triple Negative Breast Neoplasms, Antígens, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Intercellular Signaling Peptides and Proteins::B7 Antigens::B7-H1 Antigen, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, B7-H1 Antigen, [SDV.CAN] Life Sciences [q-bio]/Cancer, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Pathology, Biomarkers, Tumor, RB1-214, Humans, Other subheadings::Other subheadings::Other subheadings::/drug therapy, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::péptidos y proteínas de señalización intercelular::antígenos B7::antígeno B7-H1, Marcadors tumorals, Original Articles, 10174 Clinic for Gynecology, Progression-Free Survival, 3. Good health, 2734 Pathology and Forensic Medicine, [SDV] Life Sciences [q-bio], triple‐negative breast cancer, PD‐L1, Mama - Càncer - Tractament, Mama - Càncer - Aspectes genètics, pembrolizumab

File Description: application/pdf; ZORA_261153.pdf - application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38627977
https://hdl.handle.net/11351/11362
https://doaj.org/article/42c035448af94e8fbfc51bd921ef67f3
https://hal.science/hal-05142021v1
https://hal.science/hal-05142021v1/document
https://doi.org/10.1002/2056-4538.12371
https://www.zora.uzh.ch/id/eprint/261153/
https://doi.org/10.5167/uzh-261153

Converging and evolving immuno-genomic routes toward immune escape in breast cancer

Authors: Juan Blanco-Heredia, Carla Anjos Souza, Juan L. Trincado, Maria Gonzalez-Cao, Samuel Gonçalves-Ribeiro, Sara Ruiz Gil, Dmytro Pravdyvets, Samandhy Cedeño, Maurizio Callari, Antonio Marra, Andrea M. Gazzo, Britta Weigelt, Fresia Pareja, Theodore Vougiouklakis, Achim A. Jungbluth, Rafael Rosell, Christian Brander, Francesc Tresserra, Jorge S. Reis-Filho, Daniel Guimarães Tiezzi, Nuria de la Iglesia, Holger Heyn, Leticia De Mattos-Arruda

Contributors: Institut Català de la Salut, [Blanco-Heredia J] IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain. Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Anjos Souza C] IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain. Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. [Trincado JL] Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain. Josep Carreras Leukemia Research Institute, Barcelona, Spain. [Gonzalez-Cao M] Dexeus Institute of Oncology, Quironsalud Group, Barcelona, Spain. [Gonçalves-Ribeiro S] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ruiz Gil S] Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Nat Commun
Nature Communications
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)

Subject Terms: 0301 basic medicine, Science, Breast Neoplasms, Triple Negative Breast Neoplasms, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Article, 03 medical and health sciences, Metàstasi, Resposta immunitària, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Tumor Microenvironment, Humans, FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral, ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica, 0303 health sciences, DISCIPLINAS Y OCUPACIONES::disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::biología::biología computacional::genómica, Genomics, FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::escape del tumor, 3. Good health, DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis, Genòmica, PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment, Mama - Càncer - Aspectes genètics, Female, DISCIPLINES AND OCCUPATIONS::Natural Science Disciplines::Biological Science Disciplines::Biology::Computational Biology::Genomics, PHENOMENA AND PROCESSES::Immune System Phenomena::Tumor Escape

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38383522
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15226
https://hdl.handle.net/11351/12661
https://doaj.org/article/14cae652f3b14f88b2b7c2b80f375b63
https://ddd.uab.cat/record/301891

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

Authors: Min Huang, Amin Haiderali, Grace E. Fox, Andrew Frederickson, Javier Cortes, Peter A. Fasching, Joyce O’Shaughnessy

Contributors: Institut Català de la Salut, [Huang M, Haiderali A] Merck & Co., Inc., Kenilworth, NJ, USA. [Fox GE, Frederickson A] PRECISIONheor, New York, NY, USA. [Cortes J] International Breast Cancer Center (IBCC), Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fasching PA] Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen, EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen, Nuremberg, Erlangen, Germany. [O'Shaughnessy J] Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, TX, USA, Vall d'Hebron Barcelona Hospital Campus

Source: Pharmacoeconomics
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Subject Terms: Assistència sanitària - Cost, Other subheadings::Other subheadings::/therapy, HEALTH CARE::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Health Care Costs, Triple Negative Breast Neoplasms, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, ATENCIÓN DE SALUD::economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::costes de la atención a la salud, 3. Good health, 03 medical and health sciences, Otros calificadores::Otros calificadores::/terapia, 0302 clinical medicine, Cost of Illness, Mama - Càncer - Tractament, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Quality of Life, Humans, Female, Systematic Review, Neoplasm Recurrence, Local

File Description: application/pdf

Access URL: https://link.springer.com/content/pdf/10.1007/s40273-021-01121-7.pdf
https://pubmed.ncbi.nlm.nih.gov/35112331
https://hdl.handle.net/11351/8084

Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer

Authors: Saini, Kamal S., Vidal, Laura, Slebe, F., Loibl, Sibylle, Quintana, Angela, Peg, Vicente

Contributors: Institut Català de la Salut, Quintana A Breast Cancer Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Saini KS Fortrea, Inc., Durham, USA. Addenbrooke’s Hospital, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK. Vidal L Fortrea, Inc., Durham, USA. Peg V Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament of Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Slebe S Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Oncoclínicas & Co, Jersey City, New Jersey and Sao Paulo, Brazil. Loibl S German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany, Vall d'Hebron Barcelona Hospital Campus

Source: Scientia

Subject Terms: Mama - Càncer - Tractament, Mama - Càncer - Immunoteràpia, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological, Other subheadings::Other subheadings::/therapeutic use, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica, Otros calificadores::Otros calificadores::/uso terapéutico

File Description: application/pdf

Relation: ESMO Open;9(10); https://doi.org/10.1016/j.esmoop.2024.103713; https://hdl.handle.net/11351/12184; 001329647000001

Availability: https://hdl.handle.net/11351/12184
https://doi.org/10.1016/j.esmoop.2024.103713

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple‐negative breast cancer

Authors: Laura Pascual‐Reguant, Queralt Serra‐Camprubí, Debayan Datta, Damiano Cianferoni, Savvas Kourtis, Antoni Gañez‐Zapater, Chiara Cannatá, Lorena Espinar, Jessica Querol, Laura García‐López, Sara Musa‐Afaneh, Maria Guirola, Anestis Gkanogiannis, Andrea Miró Canturri, Marta Guzman, Olga Rodríguez, Andrea Herencia‐Ropero, Joaquin Arribas, Violeta Serra, Luis Serrano, Tian V Tian, Sandra Peiró, Sara Sdelci

Contributors: Institut Català de la Salut, [Pascual-Reguant L, Datta D, Cianferoni D, Kourtis S, Gañez-Zapater A] Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain. [Serra-Camprubí Q, Querol J, Guzman M, Rodríguez O, Herencia-Ropero A, Serra V, Tian TV, Peiró S] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Miró Canturri A] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. [Arribas J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. Centro de Investigación Biomèdica en Red de Càncer, Monforte de Lemos, Madrid, Spain. Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: EMBO Mol Med
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
EMBO Molecular Medicine, Vol 15, Iss 12, Pp 1-23 (2023)

Subject Terms: combinatorial therapy, Medicine (General), Combinatorial therapy, Cell Cycle Proteins, Triple Negative Breast Neoplasms, QH426-470, Cell cycle, Cicle cel·lular, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Bromodomain Containing Proteins, Mediator Complex Subunit 1, R5-920, Triple-negative breast cancer, Cell Line, Tumor, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Genetics, Humans, Animals, FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::ciclo celular, Cancer, Cell Proliferation, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::factores de transcripción, PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cell Cycle, Cell Cycle, Nuclear Proteins, Articles, 3. Good health, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Transcription Factors, Gene Expression Regulation, Neoplastic, triple‐negative breast cancer, Factors de transcripció, gene expression, Mama - Càncer - Aspectes genètics, cell cycle, Gene expression, Amino Acid Oxidoreductases, Transcription Factors

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37937685
https://hdl.handle.net/11351/10732
https://doaj.org/article/a9ac7e4ea8d342f3a90f379ec5eb682e
https://ddd.uab.cat/record/304951

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

Authors: Zhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, Rosa I. Gallagher, Cristina Saura, Paolo G. Nuciforo, Isabel Calvo, Jay Andersen, José Luis Passos-Coelho, Miguel J. Gil-Gil, Begoña Bermejo, Debra A. Pratt, Eva M. Ciruelos, Patricia Villagrasa, Matthew J. Wongchenko, Emanuel F. Petricoin, Mafalda Oliveira, Steven J. Isakoff

Contributors: Institut Català de la Salut, [Shi Z] Department of Oncology Biomarker, Genentech Inc., South San Francisco, California. [Wulfkuhle J, Gallagher RI] Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia. [Nowicka M] F. Hoffmann-La Roche Ltd, Basel, Switzerland. [Saura C, Oliveira M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Nuciforo PG] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Clin Cancer Res
CLINICAL CANCER RESEARCH
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Clinical cancer research : an official journal of the American Association for Cancer Research

Subject Terms: 0301 basic medicine, 0303 health sciences, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Paclitaxel, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Class I Phosphatidylinositol 3-Kinases, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Medicaments antineoplàstics - Ús terapèutic, Triple Negative Breast Neoplasms, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Neoadjuvant Therapy, Piperazines, Precision Medicine and Imaging, 3. Good health, Phosphatidylinositol 3-Kinases, 03 medical and health sciences, Pyrimidines, Mama - Càncer - Tractament, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Proto-Oncogene Proteins c-akt, Biomarkers

File Description: application/pdf; application/vnd.openxmlformats-officedocument.spreadsheetml.sheet

Access URL: https://pubmed.ncbi.nlm.nih.gov/34907082
https://incliva.fundanetsuite.com/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16447
https://hdl.handle.net/11351/9351
https://hdl.handle.net/20.500.12530/97914
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16447

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

Authors: Synnøve Yndestad, Christina Engebrethsen, Andrea Herencia-Ropero, Oleksii Nikolaienko, Olav K. Vintermyr, Reidun K. Lillestøl, Laura Minsaas, Beryl Leirvaag, Gjertrud T. Iversen, Bjørnar Gilje, Egil S. Blix, Helge Espelid, Steinar Lundgren, Jürgen Geisler, Hildegunn S. Aase, Turid Aas, Einar G. Gudlaugsson, Alba Llop-Guevara, Violeta Serra, Emiel A.M. Janssen, Per E. Lønning, Stian Knappskog, Hans P. Eikesdal

Contributors: Institut Català de la Salut, [Yndestad S, Engebrethsen C, Nikolaienko O, Lillestøl RK] Department of Oncology, Haukeland University Hospital, Bergen, Norway. K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway. [Herencia-Ropero A, Llop-Guevara A, Serra V] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Vintermyr OK] Department of Pathology, Haukeland University Hospital, Bergen, Norway. The Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway, Vall d'Hebron Barcelona Hospital Campus

Source: JCO Precis Oncol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
JCO Precision Oncology (JCO PO)

Subject Terms: FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación, Genes, BRCA2, FENÓMENOS Y PROCESOS::fenómenos genéticos::recombinación genética::recombinación homóloga, Triple Negative Breast Neoplasms, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, B7-H1 Antigen, 3. Good health, Anomalies cromosòmiques, PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Original Reports, Mutation, Mama - Càncer - Aspectes genètics, Humans, VDP::Medisinske Fag: 700, PHENOMENA AND PROCESSES::Genetic Phenomena::Recombination, Genetic::Homologous Recombination, Recombinació genètica, Homologous Recombination

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38039432
https://hdl.handle.net/11351/10783
https://hdl.handle.net/10037/32932
https://hdl.handle.net/11250/3118957

Evaluation of triple negative breast cancer with heterogeneous immune infiltration

Authors: Ángela Quintana, Enrique Javier Arenas, Cristina Bernadó, José Fernández Navarro, Jonatan González, Anna Esteve-Codina, Teresa Moliné, Merce Marti, Giuseppe Curigliano, Peter Schmid, Vicente Peg, Joaquín Arribas, Javier Cortés

Contributors: Institut Català de la Salut, [Quintana Á] Breast Cancer Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Arenas EJ] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. [Bernadó C] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fernández Navarro J, González J] Bioinformatics Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Esteve-Codina A] CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Universitat Pompeu Fabra (UPF), Barcelona, Spain. [Moliné T] Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Peg V] Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Arribas J] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain. Departament de Medicina i Ciències de la Vida, Universitat Pompeu Fabra, Barcelona, Spain. Catalan Institution for Research and Advanced Studies, (ICREA), Barcelona, Spain. Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain. [Cortés J] Breast Cancer Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. International Breast Cancer Center, Pangaea Oncology, Quironsalud Group, Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

Source: Front Immunol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Frontiers in Immunology, Vol 14 (2023)

Subject Terms: Mama - Càncer - Prognosi, Immune cell abundance, immune cell abundance, Immunology, ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::Lymphocytes, Tumor-Infiltrating, intratumor heterogeneity, Triple Negative Breast Neoplasms, Limfòcits, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos, Tumor-infiltrating lymphocytes, transcriptomics, Lymphocytes, Tumor-Infiltrating, SDG 3 - Good Health and Well-being, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms, Biomarkers, Tumor, Humans, Triple negative breast cancer, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico, Transcriptomics, Marcadors tumorals, ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos infiltrantes de tumor, RC581-607, Prognosis, 3. Good health, tumor-infiltrating lymphocytes, triple negative breast cancer, Intratumor heterogeneity, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis, Immunologic diseases. Allergy

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37215143
https://hdl.handle.net/11351/9655
https://doaj.org/article/b12b9107a3c848078a4ede6efaf4d2df
https://ddd.uab.cat/record/306168